

# EXPERIENCE OF TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITH RESPIRATORY FLUOROQUINOLONE SPARFLOXCIN

*Zh. D. Semidotskaya, O. S. Bilchenko,  
I. A. Chernyakova, V. A. Klapoukh*

## *Summary*

There were studied the efficacy and safety of sparfloxacin "Sparflo" (400 mg daily in 1st day and 200 mg daily in consecutive 6 days) in treatment of 16 patients with community-acquired pneumonia of 3rd clinical group. It was proved that sparfloxacin "Sparflo" was an effective antibiotic for treatment of group 3 community-acquired pneumonia patients. Adverse reactions were not registered during the treatment with Sparflo. Due to good tolerance and convenience of use (once daily oral formulation) Sparflo may be used for outpatient treatment of 3rd clinical group pneumonia.